169 related articles for article (PubMed ID: 22841436)
1. Novel 2-methoxyacylhydrazones as potent, selective PDE10A inhibitors with activity in animal models of schizophrenia.
Cutshall NS; Onrust R; Rohde A; Gragerov S; Hamilton L; Harbol K; Shen HR; McKee S; Zuta C; Gragerova G; Florio V; Wheeler TN; Gage JL
Bioorg Med Chem Lett; 2012 Sep; 22(17):5595-9. PubMed ID: 22841436
[TBL] [Abstract][Full Text] [Related]
2. N-Acylhydrazones as inhibitors of PDE10A.
Gage JL; Onrust R; Johnston D; Osnowski A; Macdonald W; Mitchell L; Urögdi L; Rohde A; Harbol K; Gragerov S; Dormán G; Wheeler T; Florio V; Cutshall NS
Bioorg Med Chem Lett; 2011 Jul; 21(14):4155-9. PubMed ID: 21696955
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia.
Menniti FS; Chappie TA; Humphrey JM; Schmidt CJ
Curr Opin Investig Drugs; 2007 Jan; 8(1):54-9. PubMed ID: 17263185
[TBL] [Abstract][Full Text] [Related]
4. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey.
Smith SM; Uslaner JM; Cox CD; Huszar SL; Cannon CE; Vardigan JD; Eddins D; Toolan DM; Kandebo M; Yao L; Raheem IT; Schreier JD; Breslin MJ; Coleman PJ; Renger JJ
Neuropharmacology; 2013 Jan; 64():215-23. PubMed ID: 22750078
[TBL] [Abstract][Full Text] [Related]
5. Discovery of benzo[d]imidazo[5,1-b]thiazole as a new class of phosphodiesterase 10A inhibitors.
Banerjee A; Narayana L; Raje FA; Pisal DV; Kadam PA; Gullapalli S; Kumar H; More SV; Bajpai M; Sangana RR; Jadhav S; Gudi GS; Khairatkar-Joshi N; Merugu RR; Voleti SR; Gharat LA
Bioorg Med Chem Lett; 2013 Dec; 23(24):6747-54. PubMed ID: 24231362
[TBL] [Abstract][Full Text] [Related]
6. PDE10A inhibitors: an assessment of the current CNS drug discovery landscape.
Chappie T; Humphrey J; Menniti F; Schmidt C
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):458-67. PubMed ID: 19562642
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 4-hydroxy-1,6-naphthyridine-3-carbonitrile derivatives as novel PDE10A inhibitors.
Bauer U; Giordanetto F; Bauer M; O'Mahony G; Johansson KE; Knecht W; Hartleib-Geschwindner J; Carlsson ET; Enroth C
Bioorg Med Chem Lett; 2012 Mar; 22(5):1944-8. PubMed ID: 22321214
[TBL] [Abstract][Full Text] [Related]
8. Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia.
Helal CJ; Kang Z; Hou X; Pandit J; Chappie TA; Humphrey JM; Marr ES; Fennell KF; Chenard LK; Fox C; Schmidt CJ; Williams RD; Chapin DS; Siuciak J; Lebel L; Menniti F; Cianfrogna J; Fonseca KR; Nelson FR; O'Connor R; MacDougall M; McDowell L; Liras S
J Med Chem; 2011 Jul; 54(13):4536-47. PubMed ID: 21650160
[TBL] [Abstract][Full Text] [Related]
9. Addressing phototoxicity observed in a novel series of biaryl derivatives: discovery of potent, selective and orally active phosphodiesterase 10A inhibitor ASP9436.
Hamaguchi W; Masuda N; Miyamoto S; Kikuchi S; Narazaki F; Shiina Y; Seo R; Amano Y; Mihara T; Moriguchi H; Hattori K
Bioorg Med Chem; 2015 Jul; 23(13):3351-67. PubMed ID: 25960322
[TBL] [Abstract][Full Text] [Related]
10. Novel triazines as potent and selective phosphodiesterase 10A inhibitors.
Malamas MS; Stange H; Schindler R; Lankau HJ; Grunwald C; Langen B; Egerland U; Hage T; Ni Y; Erdei J; Fan KY; Parris K; Marquis KL; Grauer S; Brennan J; Navarra R; Graf R; Harrison BL; Robichaud A; Kronbach T; Pangalos MN; Brandon NJ; Hoefgen N
Bioorg Med Chem Lett; 2012 Sep; 22(18):5876-84. PubMed ID: 22902656
[TBL] [Abstract][Full Text] [Related]
11. Highly potent, selective, and orally active phosphodiesterase 10A inhibitors.
Malamas MS; Ni Y; Erdei J; Stange H; Schindler R; Lankau HJ; Grunwald C; Fan KY; Parris K; Langen B; Egerland U; Hage T; Marquis KL; Grauer S; Brennan J; Navarra R; Graf R; Harrison BL; Robichaud A; Kronbach T; Pangalos MN; Hoefgen N; Brandon NJ
J Med Chem; 2011 Nov; 54(21):7621-38. PubMed ID: 21988093
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel orally bioavailable phosphodiesterase 10A (PDE10A) inhibitor with efficacy in animal models of schizophrenia.
Bartolomé-Nebreda JM; Alonso de Diego SA; Artola M; Delgado F; Delgado Ó; Martín-Martín ML; Martínez-Viturro CM; Pena MÁ; Tong HM; Van Gool M; Alonso JM; Fontana A; Macdonald GJ; Megens A; Langlois X; Somers M; Vanhoof G; Conde-Ceide S
J Med Chem; 2015 Jan; 58(2):978-93. PubMed ID: 25495129
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a potent, selective, and orally active phosphodiesterase 10A inhibitor for the potential treatment of schizophrenia.
Bartolomé-Nebreda JM; Delgado F; Martín-Martín ML; Martínez-Viturro CM; Pastor J; Tong HM; Iturrino L; Macdonald GJ; Sanderson W; Megens A; Langlois X; Somers M; Vanhoof G; Conde-Ceide S
J Med Chem; 2014 May; 57(10):4196-212. PubMed ID: 24758746
[TBL] [Abstract][Full Text] [Related]
14. Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors.
Höfgen N; Stange H; Schindler R; Lankau HJ; Grunwald C; Langen B; Egerland U; Tremmel P; Pangalos MN; Marquis KL; Hage T; Harrison BL; Malamas MS; Brandon NJ; Kronbach T
J Med Chem; 2010 Jun; 53(11):4399-411. PubMed ID: 20450197
[TBL] [Abstract][Full Text] [Related]
15. Patented PDE10A inhibitors: novel compounds since 2007.
Kehler J; Kilburn JP
Expert Opin Ther Pat; 2009 Dec; 19(12):1715-25. PubMed ID: 19939189
[TBL] [Abstract][Full Text] [Related]
16. The SAR development of dihydroimidazoisoquinoline derivatives as phosphodiesterase 10A inhibitors for the treatment of schizophrenia.
Ho GD; Michael Seganish W; Bercovici A; Tulshian D; Greenlee WJ; Van Rijn R; Hruza A; Xiao L; Rindgen D; Mullins D; Guzzi M; Zhang X; Bleickardt C; Hodgson R
Bioorg Med Chem Lett; 2012 Apr; 22(7):2585-9. PubMed ID: 22377514
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia.
Grauer SM; Pulito VL; Navarra RL; Kelly MP; Kelley C; Graf R; Langen B; Logue S; Brennan J; Jiang L; Charych E; Egerland U; Liu F; Marquis KL; Malamas M; Hage T; Comery TA; Brandon NJ
J Pharmacol Exp Ther; 2009 Nov; 331(2):574-90. PubMed ID: 19661377
[TBL] [Abstract][Full Text] [Related]
18. In vivo pharmacological characterization of TAK-063, a potent and selective phosphodiesterase 10A inhibitor with antipsychotic-like activity in rodents.
Suzuki K; Harada A; Shiraishi E; Kimura H
J Pharmacol Exp Ther; 2015 Mar; 352(3):471-9. PubMed ID: 25525190
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.
Verhoest PR; Chapin DS; Corman M; Fonseca K; Harms JF; Hou X; Marr ES; Menniti FS; Nelson F; O'Connor R; Pandit J; Proulx-Lafrance C; Schmidt AW; Schmidt CJ; Suiciak JA; Liras S
J Med Chem; 2009 Aug; 52(16):5188-96. PubMed ID: 19630403
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors.
Chappie TA; Humphrey JM; Allen MP; Estep KG; Fox CB; Lebel LA; Liras S; Marr ES; Menniti FS; Pandit J; Schmidt CJ; Tu M; Williams RD; Yang FV
J Med Chem; 2007 Jan; 50(2):182-5. PubMed ID: 17228859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
